RecruitingNCT06502964
ALTO-101 or placebo patch for cognition in people with schizophrenia
About this title
Read the official source — NCT06502964Medication studyAges 21–55United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Garden Grove and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 11, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 82
- Sponsor
- Alto Neuroscience
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Device, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT06502964
- Official title
Show the full official title
Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Garden Grove · Los Angeles · Orange
9 more locations
- Walnut Creek
- Hollywood
- Tampa
- Snellville
- Chicago
- Gaithersburg
- Belmont
- New York
- White Plains
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alto Neuroscience.
Does this study involve medication?
Yes. The study involves medication, including ALTO-101 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
